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Candida infective endocarditis is a rare disease with a highmortality rate. Our understanding of this infection is derived from
case series, case reports, and small prospective cohorts. The purpose of this study was to evaluate the clinical features and use of
different antifungal treatment regimens for Candida infective endocarditis. This prospective cohort study was based on 70 cases
of Candida infective endocarditis from the International Collaboration on Endocarditis (ICE)-Prospective Cohort Study and
ICE-Plus databases collected between 2000 and 2010. The majority of infections were acquired nosocomially (67%). Congestive
heart failure (24%), prosthetic heart valve (46%), and previous infective endocarditis (26%) were common comorbidities. Over-
all mortality was high, with 36%mortality in the hospital and 59% at 1 year. On univariate analysis, older age, heart failure at
baseline, persistent candidemia, nosocomial acquisition, heart failure as a complication, and intracardiac abscess were associ-
ated with higher mortality. Mortality was not affected by use of surgical therapy or choice of antifungal agent. A subgroup analy-
sis was performed on 33 patients for whom specific antifungal therapy information was available. In this subgroup, 11 patients
received amphotericin B-based therapy and 14 received echinocandin-based therapy. Despite a higher percentage of older pa-
tients and nosocomial infection in the echinocandin group, mortality rates were similar between the two groups. In conclusion,
Candida infective endocarditis is associated with a highmortality rate that was not impacted by choice of antifungal therapy or
by adjunctive surgical intervention. Additionally, echinocandin therapy was as effective as amphotericin B-based therapy in the
small subgroup analysis.
Candida infective endocarditis (CIE) accounts for only 1 to 2%of all cases of infective endocarditis (IE) (1). This infection is
important because it is associated with an exceptionally high mor-
tality rate ranging from 30 to 80% (1–5). In addition, rates of
fungemia have increased significantly in recent years, resulting in
a growing number of patients at risk for this disease (2, 6).
Due to its rarity, our understanding of the clinical features,
treatment, and mortality of CIE has been derived predomi-
nantly from retrospective reviews of case series, case reports,
and several small prospective series (1, 2, 7). The standard-of-
care treatment for CIE has historically been an amphotericin
B-based regimen coupled with adjunctive surgical therapy.
However, the options for treating invasive Candida infections
changed with the development of the echinocandins. Echino-
candins have fungicidal activity and exert their effect by inhib-
iting beta-glucan synthesis and disrupting the fungal cell wall.
In 2003, caspofungin, the first echinocandin, was approved as
therapy for invasive candidiasis, and since that time there has
been a small but growing body of literature regarding echino-
candin use in CIE (1, 2, 8–13). This has resulted in the addition
of echinocandins to both the most recent Infectious Diseases
Society of America (IDSA) and European Society for Microbi-
ology and Clinical Infectious Diseases (ESCMID) guidelines
for treatment of CIE, which now recommend either an ampho-
tericin B-based regimen or an echinocandin-based regimen,
both of these in combination with adjunctive surgical therapy
if possible (14, 15). Nevertheless, these guidelines are based
largely on case reports, case series, and clinical experience. To
date, the largest prospective series have included 30 and 33
patients, respectively (1, 2). Additionally, there are no studies
to date comparing amphotericin B- to echinocandin-based
therapy for candidal infective endocarditis.
In this study, we used two large, contemporary, multina-
tional, prospective cohorts of patients to better investigate the
clinical features, treatment, and predictors of mortality in pa-
tients with CIE. Additionally, we compared amphotericin B- to
echinocandin-based therapy in a subset of the cohort.
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MATERIALS AND METHODS
Study design. Data for this observational cohort study were derived from
the International Collaboration on Endocarditis Prospective Cohort
Study (ICE-PCS) and ICE-Plus databases. ICE-PCS and ICE-Plus have
each been previously described, including a detailed description of the
ICE organization and methodologies for data collection and cataloging (3,
16, 17). Briefly, the ICE-PCS database contains prospective data on 4,794
patients with definite IE from 64 sites in 28 countries occurring between
June 2000 and September 2006. The ICE-Plus database contains prospec-
tive data on 1,112 patients with definite IE from 29 sites in 16 countries
occurring between September 2008 and December 2010. Data for each of
these databases were gathered prospectively via a case report form (CRF)
developed by ICE collaborators according to standard definitions (3, 18).
Additionally, for this study, a supplemental CRF was sent to enrolling sites
from which cases of CIE were identified. This supplemental CRF was
designed to obtain detailed information regarding antifungal therapy and
additional risk factors for CIE, as well as 42-day follow-up information.
The ICE databases are maintained at the Duke Clinical Research Institute
(DCRI), which serves as the coordinating center for the ICE studies, with
institutional review board approvals from the Duke University School of
Medicine and the participating ICE-PCS and ICE-Plus sites.
Study population. Patients were included in this study if they met
both of the following criteria: (i) diagnosis of definite IE by the modified
Duke criteria (19) and (ii) fungal IE caused by a Candida species only.
Only patients for whom supplemental CRF information was obtained
were included in the subgroup analysis specifically examining the associ-
ation between antifungal therapy and outcomes.
Definitions. Infective endocarditis was defined according to the mod-
ified Duke criteria (19). A predisposing valvular condition was defined as
having a native valve known to be affected at baseline by regurgitation or
stenosis. Liver disease included a composite of mild, moderate, and severe
disease as defined by a Child’s Pugh score of5. Renal disease was defined
as a composite of acute kidney injury (AKI), chronic kidney disease
(CKD) at all stages, and end-stage renal disease (ESRD), including pa-
tients on hemodialysis (HD). Endocavitary device included the presence
of either a pacemaker, an internal cardiac defibrillator (ICD), a left ven-
tricular assist device (LVAD), or a right ventricular assist device (RVAD).
The presence of any prosthetic material was defined to include patients
who had any of the following: prosthetic valve, endocavitary device, in-
travenous graft material, prosthetic joint, orthopedic rod, and bone plates
or screws.
Hospital-acquired IE was defined as IE developing in a patient hospi-
talized for more than 48 h prior to the onset of signs/symptoms consistent
with IE. Health care-associated IE was defined as IE diagnosed within 48 h
of admission in an outpatient with extensive health care contact as re-
flected by any of the following criteria: (i) receipt of intravenous therapy,
wound care, or specialized nursing care at home within the 30 days prior
to the onset of infection; (ii) attendance at a hospital or hemodialysis
clinic or receipt of intravenous chemotherapy within the 30 days before
the onset of infection; (iii) hospitalization in an acute care hospital for 2 or
more days in the 90 days before the onset of infection; or (iv) residence in
a nursing home or long-term care facility (20). Community-acquired
IE was defined as IE diagnosed at the time of admission (or within 48
h of admission) in a patient not fulfilling the criteria for health care-
associated IE.
Paravalvular complication was defined as the presence of any of the
following in a patient with native valve IE: paravalvular abscess, paraval-
vular fistula, or valvular perforation. Prosthetic valve complication was
defined as the presence of any of these same complications in a patient
with prosthetic valve IE. Persistently positive blood culture was defined as
having positive blood cultures 72 h following initiation of antifungal
therapy.
For the subgroup analysis on antifungal therapy, patients were as-
signed to treatment groups based on the antifungal drug that they received
for the majority of the first 30 days of therapy. These groups were termed
majority regimen backbone groups. Patients receiving an echinocandin-
based regimen for15 days of the first 30 days of treatment were classified
as being in the echinocandin backbone therapy group, and those receiving
an amphotericin B-based regimen for 15 days of the first 30 days of
treatment were placed in the amphotericin B backbone therapy group. An
amphotericin B-based regimen was defined as a regimen that included any
of the following: amphotericin B deoxycholate, amphotericin B colloidal
dispersion (ABCD), amphotericin B lipid complex (ABLC), or amphoter-
icin B liposomal formulation (LAmB). An echinocandin-based regimen
was defined as a regimen that contained caspofungin, micafungin, or
anidulafungin. A treatment regimen was defined as a majority combina-
tion therapy regimen if the patient received at least two antifungal drugs
concomitantly for 15 days of the first 30 days of therapy. A treatment
regimen was defined as receiving any combination therapy if the patient
received1 day of two antifungal drugs concomitantly at any point dur-
ing therapy. Suppressive antifungal therapy was defined as transition of
antifungal therapy to azole-based therapy following initial treatment pe-
riod for patients treated with either amphotericin B- or echinocandin-
based therapy. For patients treated from onset of infection with azole-
based therapy, suppressive therapy was defined as a duration of azole
therapy of120 days.
Outcomes. Clinical characteristics, complications (both clinical and
echocardiographic), and mortality were compared between those receiv-
ing amphotericin B-based therapy and those receiving echinocandin-
based therapy. These same variables were compared between the follow-
ing groups: (i) those receiving adjunctive surgical therapy versus those
receiving medical therapy alone and (ii) those infected with Candida al-
bicans versus those infected with Candida parapsilosis. Additionally, uni-
variate analysis was performed to look for predictors of in-hospital and
1-year mortality in the overall cohort.
Statistical analysis. All statistical analyses were performed using JMP
Pro (version 11.0). Patients’ demographics and clinical variables were
described as means and standard deviations for continuous data and pro-
portions for categorical data. The 2 or Fisher exact test was used to com-
pare categorical variables between groups, as appropriate. The Student t
test or 1-way analysis of variance (ANOVA) was used to test significant
differences of continuous variables between groups, as appropriate. A
two-tailed P value of 0.05 or less was considered significant.
RESULTS
A total of 70 cases of definite Candida infective endocarditis (CIE)
were identified, 52 cases from ICE-PCS and 18 cases from ICE-
Plus. Forty-three patients (61%) were men. The mean age was
54.3 years. The majority of patients were over the age of 50 (63%),
and nearly half were over the age of 60 (Table 1). Forty-six percent
of patients had a prosthetic cardiac valve, and 20% had an endo-
cavitary device. The most common other comorbidities were con-
gestive heart failure (CHF), diabetes mellitus (DM), and renal
disease. Twenty-six percent of patients had a history of a previous
episode of infective endocarditis (IE) (Table 1).
Over half of the infections were hospital acquired, and only
27% were community acquired (Table 1). Among the 19 patients
with community-acquired disease, 7 (37%) engaged in intrave-
nous drug abuse (IVDA). Of the remaining 12 patients with com-
munity-acquired disease, 7 had prosthetic valves (2 with a con-
comitant endocavitary device), 2 had endocavitary devices alone,
and 3 had only one of the following nonoverlapping comorbidi-
ties: HIV, renal disease, or liver disease.
The most common clinical complication was systemic embo-
lization (34%), followed by CHF (31%) and intracardiac abscess
(24%) (Table 1). Echocardiographic evidence of complications
was present in 19% of those with native valves and 34% of those
with prosthetic valves (Table 1). Sixty-one patients (87%) had
Arnold et al.
2366 aac.asm.org April 2015 Volume 59 Number 4Antimicrobial Agents and Chemotherapy
 o
n
 January 29, 2016 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
evidence of at least one clinical or echocardiographic complica-
tion.
The most common organisms isolated were C. albicans (n 
31) and C. parapsilosis (n 19), comprising over 70% of the cases
(Table 2). One patient was infected with both C. albicans and C.
parapsilosis and was excluded from the analysis comparing infec-
tions with these two organisms. Those infected with C. parapsilosis
were more likely to be diabetic (42% versus 16%, P  0.04) and
were more likely to have community-acquired infection (44%
versus 14%, P 0.04) than were those with C. albicans. The ma-
jority of other patient characteristics and outcomes were similar
between these two organisms (Table 1).
Thirty-two patients (46%) were treated with adjunctive surgi-
cal therapy. Patients receiving surgery were younger than those
receiving medical therapy alone (Table 3). Those with intracardiac
abscess were more likely to receive adjunctive surgical therapy
TABLE 1 Characteristics of overall Candida infective endocarditis cohort and comparison by species
Characteristica
No. (%)
Pb
Overall cohort
(n 70)
C. albicans
(n 31)
C. parapsilosis
(n 19)
Age (mean SD, 54.3 17.2 yr),50 yr 44 (63) 16 (52) 14 (74) 0.12
Gender, male 43 (61) 18 (58) 7 (37) 0.72
Comorbidities
Prosthetic valve 32 (46) 15 (48) 11 (58) 0.51
Predisposing valve condition 18 (26) 7 (23) 5 (26) 0.76
Previous IE 18 (26) 9 (30) 7 (37) 0.62
Renal disease 18 (26) 7 (23) 4 (21) 1.00
CHF 17 (24) 7 (23) 3 (16) 0.72
Diabetes mellitus 15 (21) 5 (16) 8 (42) 0.04
Endocavitary device 14 (20) 5 (16) 5 (26) 0.38
Hemodialysis 10 (14) 3 (10) 4 (21) 0.40
Cancer 9 (13) 7 (23) 1 (5) 0.13
IVDA 8 (11) 4 (13) 2 (11) 1.00
Congenital heart disease 8 (11) 6 (20) 0 0.07
Liver disease 6 (9) 4 (13) 1 (5) 0.64
HIV 2 (3) 1 (3) 0 1.00
Clinical complications
Embolization 24 (34) 13 (42) 5 (26) 0.26
CHF 22 (31) 11 (35) 6 (32) 0.78
Intracardiac abscess 17 (24) 9 (29) 5 (26) 0.84
Persistently positive cultures 12 (17) 7 (23) 2 (11) 0.45
Stroke 8 (11) 2 (6) 4 (21) 0.18
Mycotic aneurysm 2 (3) 0 1 (5) 0.38
Echocardiographic complications
Regurgitation 37 (54) 18 (60) 8 (42) 0.22
Vegetation 59 (84) 28 (93) 14 (74) 0.09
Paravalvular complication 13 (19) 7 (23) 2 (11) 0.45
Paravalvular perforation 2 (3) 0 0 1.00
Paravalvular abscess 11 (16) 7 (23) 2 (11) 0.45
Paravalvular fistula 2 (3) 2 (7) 0 0.51
PV complication 11 (34) 7 (47) 2 (18) 0.22
PV dehiscence 5 (15) 3 (20) 1 (9) 0.61
PV paravalvular regurgitation 10 (31) 7 (47) 1 (9) 0.08
Acquisition
Community 19 (27) 4 (14) 8 (44) 0.04
Hospital acquired 37 (53) 22 (76) 6 (33) <0.01
Health care associated 10 (14) 3 (10) 4 (22) 0.40
Unknown 4 (6) 2 (6) 1 (5) 1.00
Surgery 32 (46) 14 (45) 12 (63) 0.22
Mortality
In hospital 25 (36) 14 (45) 5 (26) 0.18
1 yr 40 (59) 19 (66) 11 (61) 0.76
a Abbreviations: IVDA, intravenous drug abuse; CHF, congestive heart failure; IE, infective endocarditis; PV, prosthetic valve.
b P value for comparison of C. albicans to C. parapsilosis. Boldface indicates statistically significant values.
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(38% versus 13%, P  0.02). All other characteristics evaluated
were similar between those receiving adjunctive surgical therapy
and those receiving medical therapy alone. There was no differ-
ence in in-hospital or 1-year mortality (Table 3).
The all-cause mortality of the overall CIE cohort was 36% in
hospital and 59% at 1 year. This did not differ by therapy or by
species. On univariate analysis, CHF at baseline was found to be a
predictor of both in-hospital and 1-year mortality (Table 4).
Other predictors of in-hospital mortality included older age and
persistently positive blood cultures, while other predictors of
1-year mortality were nosocomial acquisition of infection, CHF as
a complication, and intracardiac abscess (Table 4).
Detailed data regarding antifungal therapy were obtained for
33 patients using the supplemental CRF. The majority of patients
received either an amphotericin B-based regimen (n 11) or an
echinocandin-based regimen (n 14) (Table 5). Of the remaining
patients, 6 received primarily azole-based therapy and 2 received a
combination of amphotericin B and an echinocandin. The two
patients receiving both amphotericin B and an echinocandin as
their primary backbone regimen were excluded from the analysis
when comparing the two therapies. Overall, 45% of patients re-
ceived combination antifungal therapy at some point during
treatment. The most common concomitantly prescribed antifun-
gal was flucytosine, followed by fluconazole.
Treatment regimens were highly varied, with many patients
undergoing sequential changes in therapy. The most common
reason for a change in therapy was renal failure, followed by tran-
sition to suppressive therapy. Overall, 21/33 (64%) patients re-
ceived amphotericin B at some point during their treatment
course. Twelve of these patients (57%) developed acute kidney
injury necessitating a change in therapy: amphotericin B therapy
was discontinued altogether in 8 patients (38%) and changed to a
lipid-based preparation of amphotericin B in the remaining 4 pa-
tients. Discontinuation of therapy due to adverse events was not
observed in any patients receiving echinocandin-based therapy.
There was a higher percentage of older patients in the echino-
candin group than in the amphotericin B group (Table 5). The
majority of infections in the amphotericin B group were commu-
nity acquired (82%), compared to less than half of the infections
in the echinocandin group (42%) (P 0.05). The rates of utiliza-
tion of combination antifungal therapy, suppressive antifungal
therapy, and adjunctive surgery did not differ between the two
groups. Mortalities measured at all 3 time points (in hospital, 42
days, and 1 year) did not differ between the two groups (Table 5).
DISCUSSION
Candida IE (CIE) is a rare, but often deadly, disease. To date, our
understanding of its clinical features and treatment practices has
been based largely on case series and reports. Prospective studies
have been small, with the two largest to date including 30 and 33
patients, respectively (1, 2). An earlier study by Baddley et al. in-
cluded 33 patients from 2000 to 2005 and was the first examina-
tion of CIE cases from the ICE database (2). Our current study has
an additional 37 patients from 2005 to 2010, making it the largest
prospective study to date on this serious infection. It is also the
first to compare relatively newer antifungal therapy (echinocan-
dins) to historically standard therapy (amphotericin B).
Similar to prior studies, we found a high proportion of health
care-associated infections (1, 2). Data previously reported from
the ICE cohort showed a 51.5% incidence of health care-associ-
ated infection (2). In our current analysis, this has risen to 67%,
TABLE 3 Characteristics of those receiving adjunctive surgical
treatment versus medical therapy alone for overall cohort
Parametera
No. (%)
Pb
Adjunctive
surgery
(n 32)
Medical therapy
alone (n 38)
Age
Mean SD, yr 47.9 17.0 59.7 15.3 <0.01
50 yr 16 (50) 28 (74) 0.04
Organism
C. albicans 14 (44) 17 (45) 0.85
C. parapsilosis 12 (38) 7 (19) 0.08
Other 6 (19) 13 (35) 0.13
Community acquired 10 (36) 9 (24) 0.29
Risk factors
Prosthetic valve 15 (47) 17 (45) 0.86
Predisposing valve condition 7 (22) 11 (29) 0.50
Congenital heart disease 5 (16) 3 (8) 0.45
Endocavitary device 7 (22) 7 (18) 0.72
Previous IE 9 (28) 9 (24) 0.72
CHF 6 (19) 11 (29) 0.32
Renal disease 5 (16) 13 (34) 0.08
Liver disease 3 (9) 3 (8) 1.00
Diabetes mellitus 8 (25) 7 (18) 0.50
Cancer 3 (9) 6 (16) 0.49
IVDA 5 (16) 3 (8) 0.46
Echocardiographic complications
Regurgitation 20 (65) 17 (46) 0.13
Paravalvular complication 6 (19) 7 (19) 0.99
Prosthetic valve complication 7 (47) 4 (24) 0.27
Clinical complications
Stroke 4 (13) 4 (11) 1.00
Embolization 13 (41) 11 (29) 0.31
CHF 9 (28) 13 (34) 0.58
Intracardiac abscess 12 (38) 5 (13) 0.02
Mycotic aneurysm 1 (3) 1 (3) 1.00
Persistently positive cultures 7 (22) 5 (14) 0.53
Mortality
In hospital 12 (38) 13 (34) 0.77
1 yr 19 (66) 21 (62) 0.76
a Abbreviations: IE, infective endocarditis; CHF, congestive heart failure; IVDA,
intravenous drug abuse.
b Boldface indicates statistically significant values.
TABLE 2 Microbiology of the overall cohort
Organism
No. (%) in overall
cohort (n 70)
C. albicans 31 (44)
C. parapsilosis 19 (27)
C. tropicalis 7 (10)
C. glabrata 4 (6)
C. krusei 1 (1)
C. albicans plus C. parapsilosis 1 (1)
NOSa 7 (10)
a NOS, not otherwise specified.
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which is consistent with data indicating Candida as an emerging
pathogen for nosocomial bloodstream infections (21). In con-
junction with the high proportion of health care-associated infec-
tion was the overall advanced age of the CIE population, with
nearly half of the patients being over the age of 60. Elderly patients
with multiple comorbidities are more likely to have contact with
the health care system and thus are more likely to acquire this
predominantly nosocomial infection. With respect to communi-
ty-acquired infection, intravenous drug abuse (IVDA) is classi-
cally associated with CIE; nevertheless, fewer than half of commu-
nity-acquired CIE cases were associated with IVDA. Among those
with non-IVDA community-acquired infection, most patients
had a prosthetic valve or endocavitary device as risk factors. Com-
munity-acquired infection outside IVDA, prosthetic valve, or an
endocavitary device was exceedingly rare, occurring in only 3 pa-
tients (4%).
The mortality rate for CIE was exceptionally high in our co-
hort. The in-hospital mortality rate was over one-third, and the
1-year mortality rate approached two-thirds, similar to what has
been reported in the literature (1, 2, 7). Despite advances in anti-
fungal therapy and surgical technique, the mortality rate has re-
mained this high throughout studies over time. Furthermore, in
our study mortality did not appear to be impacted by either use of
adjunctive surgical therapy or choice of antifungal therapy. This is
likely reflective of the overall poor health of elderly hospitalized
patients with multiple comorbidities who are predisposed to ac-
quiring this infection. Indeed, baseline characteristics such as
older age, preexisting heart failure, and nosocomial acquisition
TABLE 4 Predictors of in-hospital and 1-year mortality on univariate analysis for overall Candida infective endocarditis cohorta
Parameter
In-hospital mortality, no.
positive/total no. (%) RR (95% CI)
1-yr mortality, no.
positive/total no. (%) RR (95% CI)
Organism
C. albicans 5/19 (26) 1 (ref) 11/18 (61) 1 (ref)
C. parapsilosis 14/31 (45) 1.72 (0.74–4) 19/29 (66) 1.07 (0.68–1.69)
Age (yr)
50 5/26 (19) 1 (ref) 12/22 (55) 1 (ref)
50 20/44 (45) 2.36 (1.01–5.54) 28/41 (68) 1.25 (0.81–1.93)
Comorbidities
Native valve 14/38 (37) 1 (ref) 21/32 (66) 1 (ref)
Prosthetic valve 11/32 (34) 0.93 (0.49–1.76) 19/31 (61) 0.93 (0.64–1.36)
Nondiabetic 19/55 (35) 1 (ref) 31/48 (65) 1 (ref)
Diabetes mellitus 6/15 (40) 1.16 (0.56–2.38) 9/15 (60) 0.93 (0.58–1.48)
No CHF at baseline 14/53 (26) 1 (ref) 24/47 (51) 1 (ref)
CHF at baseline 11/17 (65) 2.45 (1.38–4.33) 16/16 (100) 1.96 (1.48–2.59)
First episode of IE 19/51 (37) 1 (ref) 28/44 (64) 1 (ref)
History of previous IE 6/18 (33) 0.89 (0.43–1.88) 11/18 (61) 0.96 (0.62–1.48)
Clinical complications
No stroke 24/62 (39) 1 (ref) 36/55 (65) 1 (ref)
Stroke 1/8 (13) 0.32 (0.05–2.07) 4/8 (50) 0.76 (0.37–1.57)
No systemic embolization 17/46 (37) 1 (ref) 28/41 (68) 1 (ref)
Systemic embolization 8/24 (33) 0.90 (0.46–1.78) 12/22 (55) 0.80 (0.52–1.23)
No CHF as complication 14/48 (29) 1 (ref) 20/43 (47) 1 (ref)
CHF as complication 11/22 (50) 1.71 (0.93–3.15) 20/20 (100) 2.15 (1.56–2.96)
No intracardiac abscess 17/53 (32) 1 (ref) 27/48 (56) 1 (ref)
Intracardiac abscess 8/17 (47) 1.47 (0.77–2.78) 13/15 (87) 1.54 (1.12–2.12)
Bloodstream clearance72 h 14/56 (25) 1 (ref) 29/50 (58) 1 (ref)
Persistently positive blood cultures 9/19 (75) 3 (1.72–5.25) 9/11 (82) 1.41 (0.98–2.03)
Echocardiographic complications
No paravalvular complication 20/56 (36) 1 (ref) 31/51 (61) 1 (ref)
Paravalvular complication 4/13 (31) 0.86 (0.35–2.09) 8/11 (73) 1.20 (0.78–1.83)
No prosthetic valve complication 6/21 (29) 1 (ref) 12/21 (57) 1 (ref)
Prosthetic valve complication 5/11 (45) 1.60 (0.62–4.06) 7/10 (70) 1.22 (0.71–2.12)
Mode of acquisition
Community acquired 3/19 (16) 1 (ref) 6/16 (38) 1 (ref)
Hospital/health care associated 21/47 (45) 2.83 (0.96–8.38) 32/44 (73) 1.93 (1.01–3.74)
Therapy
Medical therapy alone 13/38 (34) 1 (ref) 21/34 (62) 1 (ref)
Adjunctive surgical therapy 12/32 (38) 1.10 (0.58–2.05) 19/29 (66) 1.06 (0.73–1.54)
a Abbreviations: CHF, congestive heart failure; IE, infective endocarditis; RR, risk ratio; CI, confidence interval; ref, reference. Boldface indicates statistically significant values.
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were all associated with higher mortality on univariate analysis.
Higher mortality was also associated with clinical developments
such as refractory candidemia and new CHF, features which may
help identify candidates for early, aggressive interventions.
Adjunctive surgical therapy has long been considered to be the
gold standard in treating CIE. The current IDSA and ESCMID
guidelines recommend surgical therapy if possible (14, 15); how-
ever, this is based largely on case series and reports as well as expert
TABLE 5 Antifungal therapy for Candida infective endocarditis subgroup analysis
Parametera
No. (%) for group:
Pb
Overall treatment subgroup
(n 33)
Amphotericin B group
(n 11)
Echinocandin group
(n 14)
Organism
C. albicans 13 (39) 3 (27) 3 (21) 1.00
C. parapsilosis 12 (36) 5 (45) 7 (50) 0.82
Other 8 (24) 2 (18) 4 (29) 0.66
Age (yr)
Mean (95% CI) 61.0 (55.5–66.4) 52.4 (43.4–61.3) 62.5 (52.6–72.4) 0.12
50 26 (79) 8 (73) 10 (71) 1.00
60 19 (58) 3 (27) 10 (71) 0.05
70 14 (42) 1 (9) 7 (50) 0.04
Community acquired 10 (31) 9 (82) 6 (42) 0.05
Risk factors
Prosthetic valve 13 (39) 3 (27) 7 (50) 0.41
Predisposing valve condition 8 (24) 4 (36) 3 (21) 0.66
Congenital heart disease 1 (3) 0 1 (7) 1.00
Endocavitary device 8 (24) 1 (9) 5 (36) 0.18
Previous IE 8 (24) 4 (36) 2 (14) 0.35
CHF 12 (36) 4 (36) 6 (43) 1.00
Intravenous catheter 16 (52) 5 (50) 4 (29) 0.40
Any prosthetic material 20 (61) 5 (45) 10 (71) 0.24
Renal disease 12 (36) 5 (45) 5 (36) 0.70
Liver disease 5 (16) 3 (33) 1 (7) 0.26
Diabetes mellitus 10 (30) 2 (18) 5 (36) 0.41
Cancer 5 (15) 0 2 (14) 0.49
IVDA 2 (6) 2 (18) 0 0.18
ICU in last 14 days 11 (33) 3 (27) 3 (21) 1.00
Surgery in last 30 days 11 (33) 3 (27) 3 (21) 1.00
TPN 7 (21) 2 (18) 2 (14) 1.00
Echocardiographic complications
Regurgitation 17 (52) 6 (55) 6 (43) 0.56
Paravalvular complication 8 (24) 2 (18) 3 (21) 1.00
Prosthetic valve complication 4 (31) 1 (33) 0 0.30
Clinical complications
Stroke 4 (13) 1 (10) 3 (21) 0.61
Embolization 11 (33) 3 (27) 4 (29) 1.00
CHF 13 (39) 3 (27) 7 (50) 0.41
Intracardiac abscess 11 (33) 5 (45) 3 (21) 0.39
Mycotic aneurysm 1 (3) 1 (10) 0 0.42
Persistently positive cultures 2 (6) 0 1 (7) 1.00
Therapy
Majority regimen combination antifungal therapy 13 (39) 5 (45) 5 (36) 0.62
Any combination antifungal therapy 15 (45) 6 (55) 6 (43) 0.56
Suppressive antifungal therapy received 14 (42) 5 (45) 6 (43) 0.90
Adjunctive surgical therapy 13 (39) 6 (55) 5 (36) 0.35
Mortality
In hospital 13 (39) 5 (45) 4 (29) 0.43
42 days 14 (42) 5 (45) 5 (36) 0.62
1 yr 21 (66) 7 (64) 9 (69) 1.00
a Abbreviations: IE, infective endocarditis; CHF, congestive heart failure; IVDA, intravenous drug abuse; ICU, intensive care unit; TPN, total parenteral nutrition.
b P value for comparison of amphotericin B-based therapy to echinocandin-based therapy. Boldface indicates statistically significant values.
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opinion. A large meta-analysis published in 2005 reported a trend
toward improved survival with surgical therapy, although this did
not meet statistical significance (odds ratio [OR], 0.56; confidence
interval [CI], 0.16 to 1.99) (7). Interestingly, in that analysis sur-
vival among those receiving combination antifungal therapies ap-
peared similar to that of those receiving adjunctive surgical ther-
apy. One conclusion suggested by the authors was that newer
antifungal therapies potentially lent hope to those who could not
undergo surgical therapy. In our study, mortality did not differ
between those undergoing surgical therapy and those receiving
medical therapy alone. The two groups appeared similar overall
with respect to distribution of comorbidities. Additionally, the
surgical group was comprised of younger patients, which should
bias the results toward a better outcome with surgical therapy over
medical therapy. Acknowledging the small numbers included in
each study, similar to the study by Steinbach et al. (7), our study
calls into question the dogma of recommending surgical therapy
for all patients with CIE, based solely on the organism.
Amphotericin B-based therapy has long been considered the
standard therapy for CIE, based largely on experience and case
series. The echinocandins are in comparison relatively new agents,
having been approved for candidemia only within the past decade.
Like amphotericin B, the echinocandins are fungicidal, and simi-
lar to the lipid formulations of amphotericin B, they have good
activity against candidal biofilms (12, 22, 23). Although the two
therapies have been compared for treatment of invasive candidi-
asis, no studies have compared them for treatment of infective
endocarditis (24).
Our study is the first to attempt to compare the amphotericin
B- and echinocandin-based therapies for CIE. Despite the limited
number of patients in the subgroup analysis comparing therapies,
there are still some important findings. There was no difference in
mortality between patients receiving the two therapies. The echi-
nocandin group had several factors that should have biased to-
ward a worse outcome, including a statistically significant higher
percentage of older patients as well as a higher percentage of nos-
ocomial infection, both of which were shown to be associated with
higher mortality on univariate analysis. Additionally, although
not statistically significant, there were a higher percentage of pa-
tients with prosthetic valves in the echinocandin group. Despite
these differences, the mortalities did not differ between the two
groups. Coupling this with the substantially lower rate of adverse
events, specifically renal failure, associated with echinocandin
therapy, echinocandin-based therapy appears to be an attractive
option for this disease. Given the observational nature of this
study and small sample size, no definitive recommendations can
be made; however, our study provides additional supporting evi-
dence for the use of echinocandins in CIE (14).
Our study, like all studies to date on CIE, is limited by small
sample size. While the overall cohort represents the largest pro-
spective cohort to date, the subgroup for antifungal therapy was
small at only 33 patients. This may have limited our ability to
demonstrate statistically significant differences between the ther-
apy groups. Additionally, we were limited to analyzing antifungal
therapy in only those patients whose enrolling sites completed the
supplemental CRF, which could result in selection bias. Although
the majority of the data were collected prospectively, the data on
antifungal therapy were obtained retrospectively. Since this is an
observational study, definitive conclusions about antifungal treat-
ment regimen cannot be drawn; however, a randomized treat-
ment trial for CIE would be logistically impossible to perform.
In conclusion, CIE is a rare but potentially devastating infec-
tion that affects older individuals with health care exposure. Al-
though our study is small, it lends support to a growing body of
evidence for the use of echinocandin-based therapy in the treat-
ment of CIE based on a lower rate of renal dysfunction and similar
mortality. Furthermore, similar to a previous study, our study
calls into question the necessity of surgical therapy as a rule in all
patients with CIE. Although the rarity of this disease makes it
challenging to investigate, future studies are needed to validate
these findings.
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